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ORIGINAL RESEARCH
Abstract: Many barriers to drug delivery into a tumor site require careful consideration when
designing a new drug. In this study, the adhesive targeting and drug specificity of modified
liposomal vesicles on human-scar-producing cells, keloid fibroblasts, were investigated. Keloids
express abundant levels of mucopolysaccharides and receptor tyrosine kinase (RTK). In this
report, the structural properties, drug release kinetics, and therapeutic availability of silk-
fibroin-coated, emodin-loaded liposomes (SF-ELP), compared with uncoated, emodin-loaded
liposomes (ELP), were investigated. SF-ELP had a highly organized lamellae structure, which
contributed to 55% of the liposomal diameter. This modified liposomal structure decreased
emodin release rates by changing the release kinetics from a swelling and diffusional process
to a purely diffusional process, probably due to steric hindrance. SF-ELP also increased
adhesion targeting to keloid fibroblasts. Increased retention of SF-ELP is most likely due to
the interaction of the fibrous protein coating around the ELP with the pericellular molecules
around the cell. SF-ELP also decreased survival rate of keloids that expressed high levels of
RTK. These results demonstrated that SF-ELP enhanced emodin delivery by improved diffusion
kinetics and specific cell targeting.
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Introduction
Barriers to drug delivery into the tumor site are numerous and require careful
consideration when designing a new drug. Drug efficacy depends on its mode of
delivery and its potency at the tumor site. An injected drug has to travel via the
vasculature path and then diffuse and disperse into interstitial space at effective
concentrations. At the site of a solid tumor, the heterogeneous vascular architecture,
heterogeneous vascular permeability, high interstitial pressures in the necrotic core,
large interstitial distance between the tissue mass and vessels, low convective transport,
acidic pH, hypoxia, and lack of lymphatic drainage are all key issues that make drug
delivery to tumors a challenge. In addition, due to relative lack of specificity of a
drug for tumor cells, administration of high dosage no doubt contributes to the
development of drug resistance and production of toxicity in normal tissues (Jain
2001). In this report we will discuss preparation and characterization of a modified
drug delivery vehicle with a two-step approach for adhesive targeting and drug
specificity against tumor cells.
Liposomes have been used to encapsulate drugs and can be controlled by pH or
temperature. Liposomes can encapsulate hydrophilic drugs within their core and
hydrophobic or lipophilic drugs in their lipid bilayer. Their size can be varied from
nanometer to micron range and they can be size-selected. Although liposomes can
reduce drug toxicity, little to no tissue specificity is associated with naked liposomes.
Active targeting of liposomes for chemotherapy is less toxic and more effective with
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increasing in vivo residence time, promoting site-specific
delivery with control release rates.
Emodin loaded in liposomes composed of 1, 2 dimyristol-
sn-glycero-3-phosphocholine (DMPC) was shown to
improve efficacy for the treatment of 32D-p210bcr-abl
leukemia by Claxton et al (2003), who patented the
development, delivery, and formulation. Emodin (3-methyl-
1, 6, 8, trihydroxyanthran-quinone), a relatively selective
receptor tyrosine kinase (RTK) inhibitor, naturally occurs
and is a promising agent for tumor patients that develop
drug resistance to other traditional remedies. In addition,
emodin has shown impressive activity with low toxicity in
vivo and in preclinical models of Her2 overexpressing breast
cancer, while sensitizing the cells to other antitumor
therapies such as cisplatin, doxorubicin, etoposide, and
paclitaxel (Zhang et al 1995, 1998, 1999).
To localize drug delivery, and increase residence time
and specificity for cell recognition of emodin loaded in
DMPC liposomes (ELP), we developed an adhesive coating
derived from silk fiber. Silk fibroin (SF), a fibrous protein
obtained from the larva of the domestic silkmoth, Bombyx
mori, is nonthrombogenic, antiinflammatory, and cell
adhesive, making it a highly biocompatible material (Santin
et al 1999). Bombyx mori SF is composed of two chains – a
heavy chain, approximately 325 kDa, and a light chain,
approximately 25 kDa – linked by a single disulfide bridge.
The heavy chain of SF is composed of crystalline and
amorphous domains (Zhou et al 2001; Altman et al 2003).
The crystalline domain consists of glycine–alanine repeats
interconnected with serine and tyrosine amino acids. The
amorphous domain consists of the more bulky amino acids
such as aspartic acid. The crystalline domains, which form
antiparallel β-sheet secondary structures, are interspersed
by the more flexible amorphous regions (Zhou et al 2001;
Altman et al 2003). The two chains are bound together by a
sericin coating and the removal of this sericin coating, before
fibroin processing, removes the thrombogenic and
inflammatory responses of SF (Santin et al 1999). Additional
properties of SF include its strong affinity to polysaccharides
(Roden et al 1985; Falini et al 2003); mechanical properties
that include high strength and flexibility (Altman et al 2003);
and swelling properties that depend on solution pH (Yeo et
al 2003). These dynamic properties of fibroin microstructure
make it a unique candidate for controlled and sustained drug
or gene delivery. Previously, peptide sequences similar to
fibroin have been conjugated with elastin to prepare particles
for the controlled delivery of naked DNA (Megeed et al
2004). Silk fibroin microspheres have also been prepared
for drug delivery applications (Yeo et al 2003).
In this study we examined the adhesive targeting and
drug specificity of modified liposomal vesicles for human-
scar-producing cells, keloid fibroblasts. Keloids are chronic
dermal wounds resulting from a cutaneous injury caused
by surgery or inflammation. They are characterized as raised
pathological scars, causing pain and persistent itching, and
are considered to be benign dermal tumors (Rockwell et al
1989; Ehrlich et al 1994; Niessen et al 1999). Chronic dermal
wounds consist of fibroblasts that overproduce collagen and
chondroitin sulfate, have high contractile activity, high levels
of secreted cytokines, and are similar to tumors in
overexpression of RTK, a transmembrane receptor that binds
to growth factors such as fibroblast growth factor (FGF)
(Mancini and Quaife 1962; Berman and Bieley 1995).
Assessment of modified liposomes on this cell line will aid
in characterization of adhesion targeting and drug specificity.
Methods and materials
Aqueous SF
Raw silk was generously donated by Dr Sam Hudson (North
Carolina State University, Raleigh, NC, USA). Sericin
coating was removed with 0.25% w/v sodium lauryl sulfate
(SDS; Sigma-Aldrich, St Louis, MO, USA) and 0.25% w/v
sodium carbonate (Sigma-Aldrich) in boiling water for 1
hour. The degummed fibroin was then washed in boiling
water for 1 hour and rinsed again in distilled water to remove
remaining sericin and surfactants. Dried SF was then
dissolved in calcium nitrate tetrahydrate (Ca(NO3)2
.4H2O;
Fisher Scientific, Pittsburgh, PA, USA) methanol solution.
To achieve this, calcium nitrate tetrahydrate was dissolved
in methanol at 1:4:2 molar ratio (Ca:H2O:MeOH) at room
temperature for 1 hour while stirring. The solution
temperature was then raised to 70 
oC and SF was added to a
final concentration of 10% w/v. The SF was allowed to
dissolve for 4 hours with continuous stirring at 70 
oC.
Aqueous SF was eventually obtained after the dissolution
mixture was dialyzed against deionized water for 4 days
with a change of water each day (6000–8000 Da MWCO;
Fisher Scientific, Pittsburgh, PA, USA). Aqueous SF was
then stored at 4 oC until used.
ELP
Emodin was dissolved in tert-butanol at 1 mg/mL and Tween
20 solution was prepared in t-butanol at 10% v/v. DMPC
was separately dissolved in tert-butanol at 5 mg/mL and thenInternational Journal of Nanomedicine 2006:1(1) 83
Silk-fibroin-coated liposomes for targeted drug delivery
5% of the 10% Tween 20 solution was added to this overall
liposomal batch. The two solutions are then mixed together
and frozen at –80 °C overnight. The ELP were lyophilized
and stored at –20 °C until used.
Silk-fibroin-coated, emodin-loaded
liposomes (SF-ELP)
Liposomes loaded with 2.86 mg of emodin were added to
1 mL of aqueous SF (1% w/v). The solution was mixed for
10 minutes with gentle agitation. The mixture was then
frozen at –80 
oC and lyophilized. To insolubilize the SF-
coated liposomes, methanol was added and mixed for
10  minutes. The methanol was then removed by
centrifugation and then allowed to evaporate in the hood
until dry. Samples (SF-ELP) were stored at –20
oC until used.
Transmission electron microscopy of
ELP and SF-ELP
Samples of ELP and SF-ELP in saline were imaged using a
JEM 1010 transmission electron microscope (TEM; JEOL
USA Inc, Peabody, MA, USA) equipped with a digital
camera. Liposomal samples were placed on a 100 mesh
formvar-coated, carbon-coated, nickel grid treated with
poly-L-lysine for 1 hour for liposome adherence. The
samples were coated with 1% ammonium molybdate with
0.02% bovine serum albumin (BSA) in distilled water for
1 minute. Samples were blotted dry and imaged.
Emodin diffusion from coated and
uncoated liposomes
Sodium chloride solution (0.9%; Sigma-Aldrich) was added
to each liposomal emodin sample. Samples (10 µL) were
removed at appropriate time points and diluted with 990 µL
saline. Absorbance readings were then obtained immediately
at 442 nm. Diffused emodin concentration was calculated
from a standard curve of emodin in dimethyl sulfoxide
(DMSO; Fisher Scientific, Pittsburgh, PA, USA). Coated
and uncoated liposomes were kept at 37 oC between time
points with gentle mixing. Three samples were measured
for each condition.
Keloid and normal fibroblast cell culture
and maintenance
Keloid fibroblasts (passage 11–17; ATCC, Manassas, VA,
USA) and normal human dermal fibroblasts (NHDF, passage
10–17; Cambrex Corp, East Rutherford, NJ, USA) were
maintained on Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum (FBS) and 1%
penicillin, streptomycin, and glutamine solution at
humidified 37 °C and 5% CO2.
Adhesion of coated and uncoated ELP
Keloid (27 380 cells/cm
2) and normal (66 667 cells/cm
2)
fibroblasts were seeded into 2-well chamber coverslips
(Fisher Scientific, Pittsburgh, PA, USA) and incubated
overnight. Cell seeding density was increased for normal
cells due to the fact that keloid fibroblasts have a larger
contact area with the surface. Medium was aspirated and
cells were rinsed once with phosphate buffered saline (PBS).
An aliquot (0.5 mL [2.86 mg/mL emodin]) of either SF-ELP
or ELP was added to each well and incubated with cells for
10 minutes. The liposomes were removed and the cells
rinsed 3 times with PBS to remove non-adherent liposomes.
Phenol red free DMEM (0.5 mL) was added and cells were
imaged on an Olympus IX70 fluorescent microscope (40×
oil magnification; Melville, NY, USA) equipped with a
Hamamatsu CCD camera (C5810 color chilled 3CCD
camera; Hamamatsu City, Japan). All images had a 0.386-
second exposure time (minimum 6 images per chamber).
Fluorescent intensity was measured using IPLabs imaging
software (Scanalytics, Fairfax, VA, USA) and normalized
to cell number per image.
Survival of keloids and fibroblasts after
exposure to ELP and SF-ELP
MTS assay (Promega, Madison, WI, USA) was performed
to assess survival rates of cells after exposure to emodin.
MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) is bioreduced by
cells into a formazan product, which is detectable by
absorbance and is directly proportional to the number of
living cells in culture. Keloids (5000 cells/well) and normal
fibroblasts (5000 cells/well) were seeded into 96-well plates
and incubated overnight. Medium was aspirated and 200 µL
of 100 µM emodin loaded in coated or uncoated liposomes
was added for 4 or 24 hours. The liposomes were removed
and 100 µL fresh media was added with 20 µL MTS reagent.
The formazan product was allowed to develop for 1 hour
and the absorbance was read at 490 nm on a MRX plate
reader (Dynex Technologies, Chantilly, VA, USA).
Absorbance was compared with that of untreated cells and
the sample number per treatment was 5.International Journal of Nanomedicine 2006:1(1) 84
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Statistical analysis
Data sets were compared using two-tailed, unpaired t tests.
p values of less than 0.05 were considered significant.
Results and discussion
Coated and uncoated liposome
structure
TEM images of SF-ELP and ELP are shown in Figure 1.
Liposome diameters of ELP and SF-ELP were
232.2 ± 28.4 nm and 316.6 ± 43.0 nm, respectively. There
was no significant difference in the overall diameter of the
liposomes before and after SF coating. Overall lamellae
thickness for ELP and SF-ELP was 26.2 ± 2.5 nm, and
80.5 ± 6.5 nm, respectively. Coating of ELP with SF
increased lamellae thickness significantly (p < 0.0001).
Lamellae morphology of ELP appeared loosely stacked. The
SF polymer coated around the existing lamellae of ELP in
a highly organized and refined manner. Thickness of the
individual fine rings around SF-ELP was 4.2 ± 0.9 nm,
significantly less (p < 0.05) than that of the rings around
ELP (9.8 ± 2.1 nm) (Table 1).
Contribution of lamella size to overall liposome diameter
was determined by calculating the ratio of lamella thickness
to diameter (Figure 2). Lamellae contributed to 25% of the
overall diameter of ELP, and 55% to the overall diameter of
SF-ELP. Silk fibroin coating increased the overall lamellae
thickness significantly (p < 0.0001) and contributed to over
half the overall diameter of SF-ELP.
Emodin release kinetics
Emodin release from ELP and SF-ELP was quantified using
a standard curve and UV-Vis spectroscopy (Figure 3). Initial
release at time zero was similar from both ELP and SF-
ELP. ELP released twice the initial amount within the first
4 hours, while emodin from the SF-ELP increased slightly
over the same amount of time. Emodin release curve showed
that approximately 70% of the emodin was released from
ELP by 6 days, whereas only about 50% was released from
SF-ELP. The rate of release of emodin from ELP was faster
than from SF-ELP. Drug release from polymeric systems
ELP
SF-ELP
100 nm 
100 nm  100 nm  100 nm 
100 nm  100 nm 
Figure 1 A representative collage of TEM images of emodin-loaded liposomes
(ELP) and silk-fibroin-coated, emodin-loaded liposomes (SF-ELP), showing a
distinct difference in the characteristics of coated and uncoated liposomes.
Table 1 Structural characteristics of emodin-loaded liposomes
(ELP) and silk-fibroin-coated, emodin-loaded enzymes (SF-ELP )
ELP SF-ELP
Liposome diameter 232.2 ± 28.4 nm 316.6 ± 43.0 nm
Lamellae thickness 26.2 ± 2.5 nm 80.5 ± 6.5 nm*
Lamella thickness 9.8 ± 2.1 nm 4.2 ± 0.9 nm†
Lamellae structure Loosely stacked Highly organized
*p < 0.0001, †p < 0.05 compared with ELP.
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Figure 3 Emodin diffusion from emodin-loaded liposomes (ELP) and silk
fibroin-coated, emodin-loaded liposomes (SF-ELP).
Figure 2 The ratio of the lamellae thickness to the overall diameter of the
liposome shows that the silk fibroin-coated, emodin-loaded liposomes (SF-ELP)
lamella contributed a significantly higher proportion to the overall diameter of
the liposome than the emodin-loaded liposomes (ELP) lamella. * p < 0.0001
compared with ELP. Error bars in Figures 2, 3, 5, and 6 are standard error of
the mean.
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has been described by the power law (Equation 1) (Siepmann
and Peppas 2001).
n t M
kt
M∞
= (1)
Where Mt and M∞ are the absolute amounts of the drug at
any time t and at infinite time or the same as the initial drug
loading concentration, respectively. k is a constant dependent
on the structural and geometric characteristics of the
liposome and n is the exponent dependent on the release
mechanism. In this study, for ELP k is 0.169/hour and n is
0.25, and for SF-ELP k is 0.0267/hour and n is 0.50.
The results from both the structural composition studies
and release kinetics describe how emodin is released
differently from ELP and SF-ELP. The release mechanism
from ELP involves the swelling of the liposomal lamellae
and then quick diffusion of emodin. The swelling of the
DMPC lamellae of ELP was shown in the TEM images
where the lamellae are loosely organized. The mechanism
of release of emodin from SF-ELP was purely diffusion and
the rate of diffusion was slower than from ELP. The tight
packing of the lamellae in a close-knit sphere indicates that
the SF coating organized the liposomal geometry. There was
no swelling of SF-ELP since the SF coating restricted the
abrupt swelling of the liposomal lamellae, where the
hydrophobic drug is trapped. In contrast, ELP appeared to
swell before emodin release. The release of emodin from
SF-ELP was probably slow due to the steric hindrance and
barrier provided by the SF coating.
Adhesive targeting
To observe if the SF coating increased adhesion of the
liposomes to target cells, ELP and SF-ELP were added to
normal and keloid fibroblasts, which express normal and
high levels of RTK, respectively. To verify the keloids were
chronic wound cells, an immunoassay was used to detect
overexpression of transforming growth factor beta 1
(TGF-β1). The keloids expressed nearly a 3-fold increase
in TGF-β1 expression over normal fibroblasts (keloids:
83.4 ± 27.8 pg/mL, normal: 30.8 ± 5.9 pg/mL). To assess
adhesion of the liposomes, cells were exposed to ELP or
SF-ELP for 10 minutes, rinsed, and the remaining liposomes
measured by fluorescence microscopy (Figure 4). The higher
intensity of emodin found on normal and keloid fibroblasts
indicates increased retention SF-ELP to cell surface
compared with ELP (p < 0.01; Figure 5). Even higher
retention of SF-ELP on keloid fibroblast indicates that SF
is targeting the keloid fibroblast over normal fibroblast
(p < 0.05; Figure 5).
The targeting of SF to keloid fibroblast can result from
a number of factors. First, SF is a fibrous protein polymer
that supports cell adhesion similar to that of adhesion to
collagen, even though it may not have the same adhesion
domains as provided by collagen (Inouye et al 1998; Unger,
Peters, Wolf et al 2004; Unger, Wolf, Peters et al 2004).
Keloids cells synthesize approximately 20 times more
collagen than normal unscarred skin (Rockwell et al 1989).
Second, SF has good binding affinity to glycoproteins and
proteoglycans (Chen et al 1997). It has been shown that
keloid scars have abundant mucopolysaccharides compared
with normal scars (Rockwell et al 1989; Ehrlich et al 1994;
Figure 5 Fluorescent intensity measurements normalized by the number of
cells per image. Cells treated with silk fibroin-coated, emodin-loaded liposomes
(SF-ELP) fluoresced more than with emodin-loaded liposomes (ELP), indicating
that more coated liposomes adhered to the cells. *p < 0.01, **p < 0.001
compared with ELP on normal fibroblasts; #p < 0.01, ##p < 0.001 compared with
SF-ELP on normal fibroblasts; $p < 0.05 compared with ELP on keloid fibroblasts.
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Figure 4 Representative images of normal and keloid fibroblast when exposed
to emodin-loaded liposomes (ELP) or silk fibroin-coated, emodin-loaded
liposomes (SF-ELP). Normal and keloid fibroblasts were more fluorescent when
exposed to SF-ELP. Fluorescence is due to the natural fluorescence of emodin.
Scale bars represent 50 µm.
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Niessen et al 1999). Third, the organized geometry of the
coated liposomal surface could influence its architecture and
mechanical properties, thus influencing interaction and
attachment with the tumor-like cells. Therefore, the SF
coating retains more drug within the liposome so that when
administered in vivo, quick leaching of the drug is reduced,
allowing enough time for the targeted cells to absorb the
drug.
Emodin efficacy and specificity
To assess the efficacy of the drug after coating the liposomes,
keloids and normal fibroblasts were exposed to SF-ELP and
ELP and survival rate was determined using a MTS assay.
Survival rate of keloids decreased to 93% and then to 75%
after exposure to ELP after 4 hours and 24 hours,
respectively (Figure 6). However, the normal fibroblasts
continued to proliferate. When keloids were exposed to SF-
ELP over the same time scale, survival rate was 79% and
57% at 4 hours and 24 hours, respectively (p < 0.05
compared with ELP at 4 hours, p < 0.001 compared with
ELP at 24 hours). Survival rate of normal fibroblasts exposed
to SF-ELP also decreased, but to a lesser degree. This study
showed the SF coating process did not affect the emodin
efficacy. In addition, it demonstrates that emodin-loaded
liposomes coated with SF increased efficacy and specificity
of emodin when applied to tumor-like cells from the keloids.
The specificity of SF-ELP is two part and is provided by
the drug emodin and the SF coating. As previously stated,
keloids overexpress RTK and are targeted by emodin, while
the overexpression of the muco-polysaccharides over the
cell surface would have attraction for the SF (Berman and
Bieley 1995; Mancini and Quaife 1962).
Conclusions
Silk-fibroin-coated, emodin-loaded liposomes (SF-ELP),
compared with uncoated, emodin-loaded liposomes (ELP),
decreased emodin release rate but increased adhesion
targeting to keloids, chronic wound cells. The definition of
targeting in this paper addresses an interaction of the SF
with cells’ pericellular coating and not necessarily a
particular receptor – ligand combination. Additional
targeting is achieved by emodin, which targets the RTK.
The goal of the SF coating is to bring the drug in close
proximity to the targeting cell, and as the drug is released
the drug binds to the targeting receptor. Silk fibroin coating
overcomes the major shortcoming of any nanoparticle,
which is the probability of a nanoscale entity colliding with
a large cell surface in the correct vicinity and remaining in
place. This occurs due to limitations of Brownian motion.
The adhesiveness or attraction of the SF to the outer muco-
polysaccharide layer increases the probability of the
nanoparticle attaching to the cell surface as it comes in
contact of the cell. In reality, the SF could be used for any
drug coating, because the localization of the drug particle
in combination with the specificity of the drug for the tumor
is what makes it unique.
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